An evidence-based review of obatoclax mesylate in the treatment of hematological malignancies
about
Targeting the apoptosis pathway in hematologic malignanciesThe BH3 Mimetic Obatoclax Accumulates in Lysosomes and Causes Their AlkalinizationActivity of distinct growth factor receptor network components in breast tumors uncovers two biologically relevant subtypesAcute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199.Pan-Bcl-2 inhibitor, GX15-070 (obatoclax), decreases human T regulatory lymphocytes while preserving effector T lymphocytes: a rationale for its use in combination immunotherapyObatoclax potentiates the cytotoxic effect of cytarabine on acute myeloid leukemia cells by enhancing DNA damage.Beyond cell death - antiapoptotic Bcl-2 proteins regulate migration and invasion of colorectal cancer cells in vitroOBATOCLAX and ABT-737 induce ER stress responses in human melanoma cells that limit induction of apoptosis.Optical properties of prodigiosin and obatoclax: action spectroscopy and theoretical calculations.Targeting protein-protein interactions in hematologic malignancies: still a challenge or a great opportunity for future therapies?Hematologic malignancies: newer strategies to counter the BCL-2 protein.Obatoclax impairs lysosomal function to block autophagy in cisplatin-sensitive and -resistant esophageal cancer cellsObatoclax, a Pan-BCL-2 Inhibitor, Targets Cyclin D1 for Degradation to Induce Antiproliferation in Human Colorectal Carcinoma Cells.Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment.Targeting the mitochondrial apoptotic pathway: a preferred approach in hematologic malignancies?Therapeutic targeting of Bcl-2 family for treatment of B-cell malignancies.Kruppel-like Pluripotency Factors as Modulators of Cancer Cell Therapeutic Responses.Comparison of in vitro antileukemic activity of obatoclax and ABT-737.Obatoclax as a perpetrator in drug-drug interactions and its efficacy in multidrug resistance cell lines.Management of myelofibrosis: JAK inhibition and beyond.Obatoclax Inhibits Alphavirus Membrane Fusion by Neutralizing the Acidic Environment of Endocytic Compartments.Obatoclax in combination with fludarabine and rituximab is well-tolerated and shows promising clinical activity in relapsed chronic lymphocytic leukemia.The Bcl-2 inhibitor Obatoclax overcomes resistance to histone deacetylase inhibitors SAHA and LBH589 as radiosensitizers in patient-derived glioblastoma stem-like cells.Novel synthetic drugs currently in clinical development for chronic lymphocytic leukemia.Development of an efficient route toward meiogynin A-inspired dual inhibitors of Bcl-xL and Mcl-1 anti-apoptotic proteins.
P2860
Q27024422-F6742E63-C21F-4240-99A6-4E4220BC86D6Q27318794-263216C3-E8D1-4B86-944F-E8EC9D8ED0DCQ33608593-9BD19893-6111-4684-975E-8E32F63E98B9Q33875554-A22BA98E-D558-4F71-BA1F-3CC400ADD69FQ34004454-D299FD39-8AA1-4F1F-8674-92DFE246FACAQ35007971-528F0BA0-7261-49C6-AB83-2D914D9D2285Q35009440-518B2E82-ECB0-42EE-87DB-BF39E3A3DC0FQ35075657-E0D3933A-A450-451E-9EA5-9B2C3EF8A126Q35676827-04D1EA68-4EC2-4C22-8418-19C4C1CCC145Q35687836-989635A6-A241-4316-A50D-06982ED5AC4CQ35979110-8257A0EA-E136-406F-85D8-33CAAA4414C6Q37046690-7DD70325-E43F-4C32-8B3B-B8A38BE4BB84Q37631444-7640D1D3-D11C-4AEB-B979-35E51B0451FFQ38110472-92609220-3E27-4B61-9CEF-2B4EF68E631CQ38193997-42213742-C5D7-4122-88AC-3DF41029877CQ38442515-11498DAA-52CC-486A-9318-96EFA445437DQ38768833-EF4BDA65-103A-4889-BDA4-EFAED6017BB1Q38793940-182423F7-9662-4440-B71C-46E79398CA13Q38845179-BC82FD55-07FB-43BD-8D0F-4CF96672C875Q39232415-221B896C-91FC-4C88-BF82-141E91EA0118Q40051547-C23194B9-7B04-4511-BA6F-65E934194CFFQ41740316-1D87FA84-B472-4583-B116-992A8B34B80CQ42277834-11B3396E-4135-44E5-8781-706B3FC3CD04Q47932240-21C311DF-3B7F-4093-943D-C9EC06CC615CQ50988795-5CB4E997-FCA1-4132-9B41-D46A1D78ABEE
P2860
An evidence-based review of obatoclax mesylate in the treatment of hematological malignancies
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
An evidence-based review of ob ...... of hematological malignancies
@ast
An evidence-based review of ob ...... of hematological malignancies
@en
type
label
An evidence-based review of ob ...... of hematological malignancies
@ast
An evidence-based review of ob ...... of hematological malignancies
@en
prefLabel
An evidence-based review of ob ...... of hematological malignancies
@ast
An evidence-based review of ob ...... of hematological malignancies
@en
P2860
P356
P1433
P1476
An evidence-based review of ob ...... of hematological malignancies
@en
P2093
Aaron D Schimmer
Carolyn A Goard
P2860
P356
10.2147/CE.S42568
P407
P577
2013-03-14T00:00:00Z